Targeting ribosome biogenesis in cancer: lessons learned and way forward

A Zisi, J Bartek, MS Lindström - Cancers, 2022 - mdpi.com
Simple Summary Cells need to produce ribosomes to sustain continuous proliferation and
expand in numbers, a feature that is even more prominent in uncontrollably proliferating …

CETSA and thermal proteome profiling strategies for target identification and drug discovery of natural products

Y Tu, L Tan, H Tao, Y Li, H Liu - Phytomedicine, 2023 - Elsevier
Background Monitoring target engagement at various stages of drug development is
essential for natural product (NP)-based drug discovery and development. The cellular …

Proteome integral solubility alteration: a high-throughput proteomics assay for target deconvolution

M Gaetani, P Sabatier, AA Saei… - Journal of proteome …, 2019 - ACS Publications
Various agents, including drugs as well as nonmolecular stimuli, induce alterations in the
physicochemical properties of proteins in cell lysates, living cells, and organisms. These …

Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay

JM Dziekan, H Yu, D Chen, L Dai, G Wirjanata… - Science translational …, 2019 - science.org
Mechanisms of action (MoAs) have been elusive for most antimalarial drugs in clinical use.
Decreasing responsiveness to antimalarial treatments stresses the need for a better …

Current advances in CETSA

TA Tolvanen - Frontiers in molecular biosciences, 2022 - frontiersin.org
Knowing that the drug candidate binds to its intended target is a vital part of drug discovery.
Thus, several labeled and label-free methods have been developed to study target …

Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays

JG Van Vranken, J Li, J Mintseris, TY Wei, CM Sniezek… - elife, 2024 - elifesciences.org
In response to an ever-increasing demand of new small molecules therapeutics, numerous
chemical and genetic tools have been developed to interrogate compound mechanism of …

Decitabine-and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network

X Gu, R Tohme, B Tomlinson, N Sakre, M Hasipek… - Leukemia, 2021 - nature.com
Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy

LC Cheung, C Aya-Bonilla, MN Cruickshank, SK Chiu… - Leukemia, 2023 - nature.com
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal
prognosis. Survival outcomes have remained static in recent decades despite treatment …

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study

R Molokie, D Lavelle, M Gowhari, M Pacini… - PLoS …, 2017 - journals.plos.org
Background Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible
global morbidity and mortality, is driven by polymerization of mutated sickle hemoglobin …

Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism

N Tsesmetzis, CBJ Paulin, SG Rudd, N Herold - Cancers, 2018 - mdpi.com
Antimetabolites, in particular nucleobase and nucleoside analogues, are cytotoxic drugs
that, starting from the small field of paediatric oncology, in combination with other …